Cost-utility analysis of ciclesonide and budesonide in the treatment of mild to moderate bronchial asthma

ZOU Jie; HUANG Jieying; WANG Lina; DU Wenwen; XU Wei

doi:10.6039/j.issn.1001-0408.2025.02.12

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of ciclesonide and budesonide in the treatment of mild to moderate bronchial asthma

更新时间：2025-02-05

- Cost-utility analysis of ciclesonide and budesonide in the treatment of mild to moderate bronchial asthma
- ZHONGGUO YAOFANG Vol. 36, Issue 2, Pages: 203-207(2025)
- 作者机构：
  
  中国药科大学国际医药商学院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.02.12
  CLC： R956;R977.1
- Published：30 January 2025，
  
  Received：04 May 2024，
  
  Revised：24 December 2024，
  
  Accepted：2024-12-25
- 稿件说明：
移动端阅览
邹杰,黄洁莹,王丽娜等.环索奈德与布地奈德治疗轻中度支气管哮喘的成本-效用分析 [J].中国药房,2025,36(02):203-207.

ZOU Jie,HUANG Jieying,WANG Lina,et al.Cost-utility analysis of ciclesonide and budesonide in the treatment of mild to moderate bronchial asthma[J].ZHONGGUO YAOFANG,2025,36(02):203-207.
邹杰,黄洁莹,王丽娜等.环索奈德与布地奈德治疗轻中度支气管哮喘的成本-效用分析 [J].中国药房,2025,36(02):203-207. DOI： 10.6039/j.issn.1001-0408.2025.02.12.

ZOU Jie,HUANG Jieying,WANG Lina,et al.Cost-utility analysis of ciclesonide and budesonide in the treatment of mild to moderate bronchial asthma[J].ZHONGGUO YAOFANG,2025,36(02):203-207. DOI： 10.6039/j.issn.1001-0408.2025.02.12.

摘要

目的

评价环索奈德（CIC）与布地奈德（BUD）用于我国轻中度支气管哮喘患者维持治疗的经济性。

方法

从中国卫生体系角度出发，以我国一项临床试验数据为基础并参考相关文献构建Markov模型，模型循环周期为1周，研究时限为60年，年贴现率为5%，以3倍2023年我国人均国内生产总值（GDP）为意愿支付（WTP）阈值，对CIC和BUD用药方案进行成本-效用分析，并进行单因素敏感性分析、概率敏感性分析及情境分析。

结果

与BUD方案相比，CIC方案的增量成本为9 401.67元，患者可多获得0.001 3质量调整生命年（QALYs），增量成本-效果比（ICER）为6 928 868.26元/QALY，远超本研究设定的WTP阈值（268 074元/QALY）。单因素敏感性分析显示，CIC、BUD的用法用量及单价是对ICER影响较大的参数；概率敏感性分析证实，基础分析结果较为稳健；情境分析结果显示，当CIC价格降价至159.95元/瓶时，CIC方案具有经济性的概率与BUD方案相当。

结论

以3倍我国人均GDP为WTP阈值，与BUD相比，CIC在当前价格下用于我国轻中度哮喘患者维持治疗不具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-utility of ciclesonide （CIC） versus budesonide （BUD） for the maintenance treatment of mild to moderate bronchial asthma.

METHODS

From the perspective of Chinese health service system， a Markov model was established based on the data from a clinical trial in China and some literature. The cycle length was 1 week， the time horizon was 60 years. A discount rate of 5% per year was applied. Cost-utility analysis was performed on therapeutic scheme of CIC and BUD using three times of China’s per capita gross domestic product （GDP） in 2023 as the threshold of willing-to-pay （WTP）. One-way sensitivity analysis， probabilistic sensitivity analysis and scenario analysis were applied to test the uncertainty of basic analysis.

RESULTS

Compared with BUD scheme， the incremental cost of the CIC scheme was 9 401.67 yuan， and the incremental quality-adjusted life years（QALYs） were 0.001 3； incremental cost-effectiveness ratio （ICER） was 6 928 868.26 yuan/QALY， far beyond the threshold of WTP 268 074 yuan/QALY. One-way sensitivity analysis showed that the usage， dosage and unit price of CIC and BUD were parameters that had a significant impact on ICER； probabilistic sensitivity analysis showed that the basic analysis results were relatively robust； scenario analysis showed that， when the price of CIC reduced to 159.95 yuan/branch， the probability of CIC scheme having economics was similar to that of BUD scheme.

CONCLUSIONS

At the current price， CIC is not economical compared with BUD for the maintenance treatment of mild to moderate asthma， using three times of China’s GDP in 2023 as the threshold of WTP.

关键词

环索奈德布地奈德支气管哮喘维持治疗成本-效用分析

Keywords

budesonidebronchial asthmamaintenance treatmentcost-utility analysis

references

胡倩，吴松泽，刘春涛. 成都地区14岁以上人群哮喘患病率及相关危险因素的流行病学调查[J]. 中国呼吸与危重监护杂志，2020，19（2）：183-189.

HU Q，WU S Z，LIU C T. Prevalence and risk factors of asthma in Chengdu among adolescents aged over 14 years and adults[J]. Chin J Respir Crit Care Med，2020，19（2）：183-189.

许珂琦，周媚娣，戚巧玲.围绝经期妇女哮喘临床发病特点、影响因素调查与防治对策研究[J].中国妇幼保健，2020，35（17）：3243-3245.

XU K Q，ZHOU M D，QI Q L. Study on the clinical cha-racteristics，influencing factors and prevention and treatment of asthma in perimenopausal women [J]. Matern Child Health Care China，2020，35（17）：3243-3245.

GBD Chronic Respiratory Disease Collaborators. Global，regional，and national deaths，prevalence，disability-adjusted life years，and years lived with disability for chronic obstructive pulmonary disease and asthma，1990-2015：a systematic analysis for the global burden of di-sease study 2015[J]. Lancet Respir Med，2017，5（9）：691-706.

WANG C，XU J Y，YANG L，et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China：the China Pulmonary Health（CPH） study：a national cross-sectional study[J]. Lancet，2018，391（10131）：1706-1717.

HUANG K W，YANG T，XU J Y，et al. Prevalence，risk factors，and management of asthma in China：a national cross-sectional study[J]. Lancet，2019，394（10196）：407-418.

Global Initiative for Asthma. Global strategy for asthma management and prevention：updated 2022[EB/OL].[2024-05-01]. https：//ginasthma.org/wp-content/uploads/2023/05/GINA-Main-Report-2022-WMSA.pdfhttps://ginasthma.org/wp-content/uploads/2023/05/GINA-Main-Report-2022-WMSA.pdf.

中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南：2020年版[J]. 中华结核和呼吸杂志，2020，43（12）：1023-1048.

Asthma Group of Chinese Thoracic Society. Guidelines for bronchial asthma prevent and management：2020 edition[J]. Chin J Tuberc Respir Dis，2020，43（12）：1023-1048.

Global Initiative for Asthma. Global strategy for asthma management and prevention：2023 update[EB/OL]. [2024-05-01]. https：//ginasthma.org/2023-gina-main-report/https://ginasthma.org/2023-gina-main-report/.

BOULET L P，DROLLMANN A，MAGYAR P，et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma[J]. Respir Med，2006，100（5）：785-794.

CHIU K C，CHOU Y L，HSU J Y，et al. Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy：a randomised parallel-group study[J]. NPJ Prim Care Respir Med，2014，24：14010.

刘国恩. 中国药物经济学评价指南：2020[M]. 北京：中国市场出版社，2020：17.

LIU G E. Guidelines for pharmacoeconomic evaluation in China： 2020[M]. Beijing：China Market Press，2020：17.

PRICE M J，BRIGGS A H. Development of an economic model to assess the cost effectiveness of asthma management strategies[J]. Pharmacoeconomics，2002，20（3）：183-194.

FITZGERALD J M，ARNETORP S，SMARE C，et al. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK[J]. Respir Med，2020，171：106079.

RODRÍGUEZ-MARTÍNEZ C E，SOSSA-BRICEÑO M P，NINO G. Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma：a cost-utility analysis in Colombia[J]. J Allergy Clin Immunol Pract，2021，9（10）：3816-3818.e2.

World Health Organization. WHO mortality database[EB/OL].[2024-05-01].https：//platform.who.int/mortalityhttps://platform.who.int/mortality.

林江涛，邢斌，唐华平，等. 2013－2014年我国城区支气管哮喘急性发作住院患者的临床特征及住院费用的回顾性调查[J]. 中华结核和呼吸杂志，2017，40（11）：830-834.

LIN J T，XING B，TANG H P，et al. A multi-center retro-spective study of clinical characteristics and hospitalization costs of patients hospitalized for asthma exacerbation in China during 2013-2014[J]. Chin J Tuberc Respir Dis，2017，40（11）：830-834.

凌怡. 急诊救护临床护理路径在哮喘患者中的应用效果[J]. 中国医药导刊，2015，17（5）：524-525.

LING Y. Application effect of clinical nursing pathway in emergency treatment in patients with asthma[J]. Chin J Med Guide，2015，17（5）：524-525.

WANG X L，FANG H H，SHEN K L，et al. Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving step 3 treatment in China[J]. J Med Econ，2020，23（12）：1630-1639.

LLOYD A，PRICE D，BROWN R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK[J]. Prim Care Respir J，2007，16（1）：22-27.

BUENDÍA J A，PATIÑO D G. Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to mo-derate persistent asthma[J]. BMC Pulm Med，2021，21（1）：397.

饶文晨，宋晓兵. 布地奈德2种吸入给药方案用于轻度哮喘的药物经济学评价[J]. 中国药房，2023，34（1）：78-81.

RAO W C，SONG X B. Pharmacoeconomic evaluation of 2 kinds of inhalation schemes of budesonide for mild asthma[J]. China Pharm，2023，34（1）：78-81.

FLEURENCE R L，HOLLENBEAK C S. Rates and pro-babilities in economic modelling：transformation，translation and appropriate application[J]. Pharmacoeconomics，2007，25（1）：3-6.

RODRÍGUEZ-MARTÍNEZ C E，SOSSA-BRICEÑO M P，CASTRO-RODRIGUEZ J A. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma[J]. J Asthma，2013，50（4）：410-418.

李冬艳，王磊. 支气管哮喘患者用药依从性及其生命质量影响因素的研究[J]. 山西医科大学学报，2008，39（2）：157-159.

LI D Y，WANG L. Study on medication compliance in bronchial asthma patients and the influential factors of quality of life[J]. J Shanxi Med Univ，2008，39（2）：157-159.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with poor glycemic control with metformin

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer

Pharmacoeconomic evaluation of clopidogrel versus aspirin for secondary prevention of ischemic stroke

Cost-utility analysis of tislelizumab monotherapy for second-line treatment of advanced or metastatic esophageal squamous cell carcinoma

Introduction of measurement methods of health utility for cancer patients

Related Author

LIU Guoqiang

NIU Mengna

GUO Shan

GAO Shengnan

FENG Bing

GAO Ning

HOU Yanhong

WU Fang

Related Institution

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Hebei Society for Integrated Drug and Health Technology Assessment

Dept. of Pharmacy， Huangpu Branch， Shanghai Ninth People’s Hospital， Shanghai Jiaotong University School of Medicine

Dept. of Pharmacy， Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Clinical Research Center， Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰